Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (October 2025)
24 slides from Medical Developments International's shareholder meeting presentation, Oct 10, 2025
Slide 1: FY25 Annual General Meeting
ASX:MVP FY25 For personal use only ANNUAL GENERAL MEETING 10 OCTOBER 2025
Slide 2: Gordon Naylor, Company Chair
For personal use only Gordon Naylor Company Chair 2
Slide 3: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 106340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 4: Important notice and disclaimer
Important notice and disclaimer Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label
Slide 5: Your Board
Your Board For personal use only Gordon Naylor Russell Basser Christine Emmanuel- Mark Fladrich Leon Hoare Paul Townsend Company Chair Independent Non-executive Donnelly Independent Non-executive Independent Non-executive Independent Non-executive Director Independent Non-executive Director Director
Slide 6: How to ask a question
How to ask a question To ask a written question select the Q & A icon For personal use only Select the topic your question relates to from the drop-down list Type your question in the text box and press the send button To ask a verbal question follow the instructions below the broadcast window. 6
Slide 7: How to vote
How to vote When the poll is open, select the vote icon at the top of the screen For personal use only To vote, select either For, Against or Abstain You will see a vote confirmation To change or cancel your vote “click here to change your vote” at any time until the poll is closed 7
Slide 8: Step-change in FY25
For personal use only 8 Step-change in FY25
Slide 9: CEO Brent MacGregor
For personal use only 9 CEO Brent MacGregor
Slide 10: FY25 Highlights
FY25 Highlights Step-change in financials • Group revenue of $39.1m (+18%) with improved results in Pain Management and Respiratory FY25 results • Margin improvements of ~$4m from enhanced pricing Margins, earnings • Significant operating cost reduction of ~$4m driven by efficiencies For personal us
Slide 11: Priorities for FY26
Priorities for FY26 Accelerating volume growth is now the key priority FY26 initiatives Accelerate penetration 1. Local and international knowledge exchange For personal use only of Penthrox® • Strong partner engagement • Support launch of paediatric label in priority European markets (following nat
Slide 12: Questions
For personal use only 12 Questions
Slide 13: Formal Business
For personal use only 13 Formal Business
Slide 14: Remuneration Report resolution
Resolution 1 For personal use only “That the Remuneration Report for the year ended 30 June 2025 as set out in the Company’s Annual Report for the year ended 30 June 2025 be adopted.” 14
Slide 15: Proxy results
Resolution 1 Proxy results For Against Open Abstain For personal use only No. Of Shares 33,044,851 469,368 220,433 6,368,036 % of Total 97.96 1.39 0.65 N/A Proxies 15
Slide 16: Re-election of Leon Hoare
Resolution 2 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Mr Leon Hoare as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring by rotatio
Slide 17: Proxy results
Resolution 2 Proxy results For Against Open Abstain For personal use only No. Of Shares 39,551,092 553,991 1,553,471 62,864 % of Total 94.94 1.33 3.73 N/A Proxies 17
Slide 18: Re-election of Christine Emmanuel-Donnelly
Resolution 3 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Ms. Christine Emmanuel-Donnelly as a Non- Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is
Slide 19: Proxy results
Resolution 3 Proxy results For Against Open Abstain For personal use only No. Of Shares 37,634,290 2,549,729 1,553,471 54,369 % of Total 90.16 6.11 3.73 N/A Proxies 19
Slide 20: Election of Mark Fladrich
Resolution 4 “That pursuant to the Company’s Constitution and for all For personal use only other purposes, the members of the Company approve the election of Mr Mark Fladrich as a Non-Executive Director of the Company, who was appointed as a director as an additional director, effective on 1 April
Slide 21: Proxy results
Resolution 4 Proxy results For Against Open Abstain For personal use only No. Of Shares 39,894,803 254,805 1,564,471 77,780 % of Total 95.63 0.62 3.75 N/A Proxies 21
Slide 22: Election of Paul Townsend
Resolution 5 “That pursuant to the Company’s Constitution and for all For personal use only other purposes, the members of the Company approve the election of Mr Paul Townsend as a Non-Executive Director of the Company, who was appointed as a director as an additional director, effective on 29 May 2
Slide 23: Proxy results
Resolution 5 Proxy results For Against Open Abstain For personal use only No. Of Shares 39,936,352 214,361 1,554,871 86,275 % of Total 95.75 0.52 3.73 N/A Proxies 23
Slide 24: Conclusion
For personal use only 24 Conclusion
Medical Developments International — Shareholder Meeting (October 2025) on 6ix